Discussing Vilobelimab Phase III Study in Severe COVID-19

Time: 8:20 am
day: Day Two


  • Reviewing how complement fragment C5a is activated by SARS-CoV-2 infection leading to neutrophil activation, reactive oxygen species generation, NETosis, release of tissue factor and fibrin formation, which contributes to a microangiopathy with thrombosis
  • Exploring Vilobelimab, a first-in-class anti-C5a monoclonal antibody, binds C5a with high affinity clearing it from circulation
  • Evaluating how Phase III results in severely ill, intubated COVID-19 patients demonstrate that vilobelimab has a clinically meaningful benefit reducing allcause 28-day mortality with a safety profile similar to standard-of-care